Aridis Pharmaceuticals founder, CEO, and Director Vu Truong, Ph. D. doesn’t think the 8,000 milligram dose of Regeneron’s SARS-CoV-2 Virus Multi-Antibody Therapy (REGN-COV2) given to President Trump is a practical approach to treating the millions affected by the disease. “That’s an incredibly expensive dose to manufacture considering that less than 1% of the medicine will actually make it to the lungs, where the infection resides,” he says, estimating the cost to manufacture at around $1k.